162 related articles for article (PubMed ID: 38570849)
21. Does the separating of hospital revenue from drug sales reduce the burden on patients? Evidence from China.
Li L; Yu Q
Int J Equity Health; 2021 Jan; 20(1):12. PubMed ID: 33407503
[TBL] [Abstract][Full Text] [Related]
22. Impacts of price changes on public hospital reforms in China: evidence from 25 million patients at tertiary hospitals.
Zhu D; Shi X; Chen S; Ye X; He P
Health Policy Plan; 2022 Nov; 37(10):1307-1316. PubMed ID: 36057091
[TBL] [Abstract][Full Text] [Related]
23. The availability, price and affordability of antidiabetic drugs in Hubei province, China.
Gong S; Cai H; Ding Y; Li W; Juan X; Peng J; Jin S
Health Policy Plan; 2018 Oct; 33(8):937-947. PubMed ID: 30215707
[TBL] [Abstract][Full Text] [Related]
24. Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015.
Śliwczyński A; Brzozowska M; Jacyna A; Iltchev P; Iwańczuk T; Wierzba W; Marczak M; Orlewska K; Szymański P; Orlewska E
PLoS One; 2017; 12(6):e0178764. PubMed ID: 28582404
[TBL] [Abstract][Full Text] [Related]
25. Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.
Lan T; Guan L; Pang X; Li X; Yu Q
J Clin Pharm Ther; 2022 Jan; 47(1):104-111. PubMed ID: 34668203
[TBL] [Abstract][Full Text] [Related]
26. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
27. Why the increase? Examining the rise in prescription medication expenditures in the United States between 2011 and 2020.
Chi W; Song J; Yazdanfard S; Daggolu J; Varisco TJ
Res Social Adm Pharm; 2024 Apr; 20(4):432-442. PubMed ID: 38302297
[TBL] [Abstract][Full Text] [Related]
28. Effects of restrictive reimbursement on the prescribing and expenditures on non-essential lipid-lowering drugs.
Limwattananon C; Soontornpas C; Waleekhachonloet O; Rattanachotphanit T; Thammatacharee N
Res Social Adm Pharm; 2020 Dec; 16(12):1664-1669. PubMed ID: 32144087
[TBL] [Abstract][Full Text] [Related]
29. Does the leading pharmaceutical reform in China really solve the issue of overly expensive healthcare services? Evidence from an empirical study.
He Y; Dou G; Huang Q; Zhang X; Ye Y; Qian M; Ying X
PLoS One; 2018; 13(1):e0190320. PubMed ID: 29338038
[TBL] [Abstract][Full Text] [Related]
30. Trends analysis for drug utilization in county public hospitals: a sample study of the pilot area of health care reform in China.
Xie X; Jin X; Zhang L; Sun H; Shen A; Huang X; Sun Y
BMC Health Serv Res; 2018 Oct; 18(1):812. PubMed ID: 30352585
[TBL] [Abstract][Full Text] [Related]
31. Do cost containment policies save money and influence physicians' prescribing behavior? Lessons from South Korea's drug policy for diabetes medication.
Kang SO; Kim SJ; Park S; Jang SI; Park EC
Int J Qual Health Care; 2019 Mar; 31(2):96-102. PubMed ID: 29788203
[TBL] [Abstract][Full Text] [Related]
32. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea.
Bae G; Park C; Lee H; Han E; Kim DS; Jang S
BMC Health Serv Res; 2014 Mar; 14():100. PubMed ID: 24589172
[TBL] [Abstract][Full Text] [Related]
33. Pharmaceutical cost-containment policy: experiences in Shanghai, China.
Hu S; Chen W; Cheng X; Chen K; Zhou H; Wang L
Health Policy Plan; 2001 Dec; 16 Suppl 2():4-9. PubMed ID: 11772985
[TBL] [Abstract][Full Text] [Related]
34. Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost?
McEwen LN; Casagrande SS; Kuo S; Herman WH
Curr Diab Rep; 2017 Sep; 17(9):71. PubMed ID: 28741264
[TBL] [Abstract][Full Text] [Related]
35. The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis.
Ding Y; Zheng C; Wei X; Zhang Q; Sun Q
BMC Public Health; 2022 Dec; 22(1):2363. PubMed ID: 36527037
[TBL] [Abstract][Full Text] [Related]
36. [Study on calculating the curative care expenditure of injury in Gansu Province based on "A System of Health Accounts 2011"].
Zhao MT; Hu YS; Qi L; Wang N; Cui QM; Cui Y; Wang LX; Hu XB
Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Sep; 53(9):900-906. PubMed ID: 31474071
[No Abstract] [Full Text] [Related]
37. Short-term and long-term effects of Sanming healthcare system reform on drug-related expenditures for rural patients with cancer in public hospitals: an interrupted time series analysis using segmented regression model in China.
Fu R; Chen Q; Lin Y; Lin Z; Zheng Z; Hu Z
BMJ Open; 2023 Jan; 13(1):e065586. PubMed ID: 36604122
[TBL] [Abstract][Full Text] [Related]
38. Economic burden of malaria inpatients during National Malaria Elimination Programme: estimation of hospitalization cost and its inter-province variation.
Tang S; Feng D; Wang R; Ghose B; Hu T; Ji L; Wu T; Fu H; Huang Y; Feng Z
Malar J; 2017 Jul; 16(1):291. PubMed ID: 28724446
[TBL] [Abstract][Full Text] [Related]
39. Use of glucose-lowering drugs in Hungary between 2008 and 2017: the increasing use of novel glucose-lowering drug groups.
Csatordai M; Benkő R; Matuz M; Bor A; Lengyel C; Doró P
Diabet Med; 2019 Dec; 36(12):1612-1620. PubMed ID: 31456231
[TBL] [Abstract][Full Text] [Related]
40. Impact of public health insurance coverage of novel anticancer medication on medical expenditure and patient affordability in a provincial medical centre of China: a propensity score-matching analysis with the quasi-experimental design.
Diao Y; Lin M; Xu K; Huang J; Wu X; Li M; Sun J; Li H
BMJ Open; 2022 Feb; 12(2):e054713. PubMed ID: 35173004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
